A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma
Latest Information Update: 11 May 2022
At a glance
- Drugs Pazopanib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-018
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharma A.G.
- 26 Apr 2019 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 Planned End Date changed from 9 Feb 2019 to 17 Apr 2019.
- 05 Sep 2018 Planned primary completion date changed from 12 Aug 2018 to 17 Apr 2019.